PLANO, Texas — 09.29.2026 — 3A Research today announced its expansion into the Dallas–Fort Worth market with the addition of 3A Research Plano, a full-service clinical research center led by Michele Reynolds, MD, CPI, and an experienced team with a more than 10-year history of conducting industry-sponsored clinical trials.
The expansion strengthens 3A Research’s ability to support pharmaceutical, biotechnology, and medical device sponsors throughout Texas with experienced investigators, broad therapeutic expertise, and proven clinical research capabilities.
Dr. Reynolds, a board-certified physician and ACRP Certified Principal Investigator (CPI), has served as a Principal Investigator since 1995. She has led hundreds of Phase I-IV clinical trials across more than 20 therapeutic areas, with a longstanding commitment to patient safety, regulatory compliance, and scientific excellence.
Joining Dr. Reynolds is a research team with more than 60 years of combined clinical research experience. Prior to joining 3A Research, the team supported more than 1,000 clinical trials across therapeutic areas including vaccines, endocrinology, cardiology, gastroenterology, dermatology, women’s health, urology, neurology, metabolic disease, and general medicine.
The Plano site offers comprehensive clinical research capabilities, including experienced study startup and regulatory personnel, GCP-trained clinical research coordinators, CLIA-certified laboratory services, ECG capabilities, PBMC processing, secure investigational product storage, dedicated participant recruitment resources, and modern clinical research facilities.
“Our expansion into the Dallas–Fort Worth market represents an important milestone in the continued growth of 3A Research,” said Andy Silverman, Chief Executive Officer of 3A Research. “More importantly, we’re adding an exceptional team with a proven record of delivering high-quality clinical trials. Dr. Michele Reynolds and her colleagues have built an outstanding reputation for operational excellence, scientific rigor, and patient-centered research, and we’re excited to welcome them to 3A Research.”
Michael Raucci, CEO of 3A Research El Paso, said, “Bringing Dr. Reynolds and her team into 3A Research strengthens our ability to serve both patients and sponsors while expanding our presence in Texas. Their experience and commitment to quality fit naturally with our organization, and we look forward to building on that foundation as we expand access to innovative clinical trials throughout the DFW metro area.”
As 3A Research expands, the organization is also investing in the next generation of clinical research professionals by recruiting talented early-career professionals and providing structured training, mentorship, and progressive career development. This approach combines experienced investigators and research leaders with the development of future clinical research talent to support consistent quality for sponsors and strengthen the clinical research workforce.
About 3A Research
3A Research is a multi-center clinical research site organization dedicated to advancing medicine through high-quality clinical trials. The company partners with pharmaceutical, biotechnology, and medical device sponsors across multiple therapeutic areas, combining experienced investigators and clinical teams with a commitment to developing the next generation of clinical research professionals.